Russian government may approve sale of drugs in convenience retail stores

24 April 2019
russia_roubles_rubles_money_big

The Russian government plans to approve the beginning of sales of drugs in convenience retail stores this year – in a move to make drugs more affordable to the local population, due to the reduction of prices for them, according to some senior officials of the Russian Ministry of Health and senior local experts in the field of pharmaceutics.

In fact, such an initiative was for the first time put forward almost 10 years ago, however, so far, its final approval has been prevented by protests of producers and analysts, reports The Pharma Letter’s local correspondent.

Analysts argue that the beginning of sales of drugs in retail will not result in the reduction of price but, in contrast, lead to their growth in some market segments, particularly prescription drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical